706811-25-8

Basic information

• Product Name: 4(1H)-PyriMidinone, 5-(4-broMophenyl)-6-hydroxy-
• Synonyms: 4(1H)-PyriMidinone, 5-(4-broMophenyl)-6-hydroxy-;5-(4-broMophenyl)pyriMidine-4,6(1H,5H)-dione;5-(4-broMophenyl)-6-hydroxy- 4(1H)-PyriMidinone;5-(4-broMophenyl)pyriMidine-4,6-diol;5-(4-Bromophenyl)-6-hydroxypyrimidin-4(1H)-one;5-(4-Bromophenyl)-4,6-pyrimidinediol
• CAS NO: 706811-25-8
• Molecular Formula: C₁₀H₇BrN₂O₂
• Molecular Weight: 267.07878
• Mol File: 706811-25-8.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Density: 1.74±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.69±0.10(Predicted)
• CAS DataBase Reference: 4(1H)-PyriMidinone, 5-(4-broMophenyl)-6-hydroxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 4(1H)-PyriMidinone, 5-(4-broMophenyl)-6-hydroxy-(706811-25-8)
• EPA Substance Registry System: 4(1H)-PyriMidinone, 5-(4-broMophenyl)-6-hydroxy-(706811-25-8)

Safety Data

• Hazardous Substances Data: 706811-25-8(Hazardous Substances Data)

Usage

Uses

5-(4-Bromophenyl)pyrimidine-4,6-diol is used in preparation of pharmaceutical intermediate of Macitentan.

InChI:InChI=1S/C10H7BrN2O2/c11-7-3-1-6(2-4-7)8-9(14)12-5-13-10(8)15/h1-5H,(H2,12,13,14,15)

Upstream product

• 6313-33-3 formamidine hydrochloride 
• 157134-36-6 dimethyl 2-(4-bromobenzyl)malonate 
• 77287-34-4 formamide 
• 149506-35-4 2-(4-bromophenyl)-malonic acid dimethyl ester 
• 3473-63-0 formamidine acetic acid 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 14062-25-0 Ethyl 4-bromophenylacetate 
• 93139-85-6 2-(4-bromophenyl)malonic acid diethyl ester 

Downstream Products

• 146533-41-7 5-(4-bromophenyl)-4,6-dichloropyrimidine 
• 1433875-21-8 ACT-080803 
• 2211059-05-9 2‐((6‐amino‐5‐(4‐bromophenyl)pyrimidin‐4‐yl)oxy)ethan‐1‐ol 
• 556797-16-1 C₂₀H₂₁Br₂N₅O₄S 
• 1393813-61-0 C₂₀H₂₀Br₂N₆O₅S 
• 1393813-60-9 C₂₄H₂₂Br₂N₆O₄S 
• 441797-02-0 C₁₉H₁₈Br₂N₆O₄S 
• 441798-39-6 C₂₀H₂₂Br₂N₆O₄S 
• 441796-13-0 C₁₈H₁₈Br₂N₆O₄S 
• 441798-25-0 C₁₇H₁₆Br₂N₆O₄S 
• 441797-01-9 C₁₅H₁₇BrN₄O₄S 
• 441796-12-9 C₁₄H₁₇BrN₄O₄S 

Relevant articles and documents

Synthetic method for macitentan drug intermediate

The invention discloses a synthetic method for a macitentan drug intermediate. The synthetic method for the macitentan drug intermediate comprises the following raw material components: 20-30 parts ofanhydrous methanol, 6-8 parts of 4-bromophenylacetic acid, 8-10 parts of sulfonyl chloride, 20-40 parts of sodium methoxide, 10-15 parts of dimethyl carbonate, 5-10 parts of formamidine hydrochloride, 60-80 parts of phosphorus oxychloride (newly evaporated) and 1-2 parts of N,N-dimethylaniline. According to the provided synthetic scheme, synthetic raw materials are simple, the purity of the obtained product is higher than that of like products, and the requirement for keeping synthesizing macitentan can be met.

Preparation method of 5-(4-bromophenyl)-4,6-dichloropyrimidine

The invention belongs to the technical field of pharmaceutical chemistry synthesis, and relates to a preparation method of 5-(4-bromophenyl)-4,6-dichloropyrimidine. The preparation method comprises the following steps: carrying out catalytic esterification on bromophenylacetic acid to prepare methyl p-bromophenylacetate, then carrying out a reaction with dimethyl carbonate to synthesize 2-(4-bromophenyl)-malonic acid-1,3-diethyl ester, carrying out cyclization by using formamidine hydrochloride to obtain 5-(4-bromophenyl)-4,6-dihydroxy pyrimidine, and then carrying out chlorination to obtain the product 5-(4-bromophenyl)-4,6-dichloropyrimidine. In the preparation process of the intermediate 1, a solid acid is adopted as a catalyst, so that the synthesis process and a post-treatment step are simplified. The solid acid is easy to separate and can be repeatedly used, so that resources are saved, and production cost is reduced. In a process of preparing the intermediate 2, sodium methoxideis adopted as an alkali to replace sodium hydride or amino sodium used in the prior art, so that production safety is improved, and production cost is reduced. Meanwhile, the intermediate 3 is prepared by adopting a one-pot method, so that operation steps are reduced.

4-PYRIMIDINESULFAMIDE DERIVATIVE

The invention relates to the compound of structural formula (I) and the salts thereof. Said compound is useful as endothelin receptor antagonist. The invention further relates to a process for preparing said compound.